Visit http://www.otcpicks.com/microcap.htm to register for our Daily Market Mover’s Digest Newsletter and Email Stock Watch Alerts.
EV INNOVATIONS INCORPORATIONS (OTCBB: EVII)
"Up 3.95% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/EVII.php
Company Profile: http://www.otcpicks.com/ev-innovations.htm
EV Innovations, Inc. engages in the development and marketing of electric powered vehicles and products primarily in the United States. It involves in developing the portable battery power pack technology and effecting vehicle conversions from conventional power systems to electric power systems. It also converts various large and small ATV's, electric bicycles, and electric scooters. The company was formerly known as Hybrid Technologies, Inc. and changed its name to EV Innovations, Inc. in February 2009. EV Innovations, Inc. was founded in 2000 and is based in Las Vegas, Nevada.
EVII News:
August 12 - EV Innovations Inc. Congratulates GM for Being the SECOND Company to Break the Triple Mileage Barrier
EV Innovations Inc. (OTCBB: EVII), a 21st Century Design & Engineering of emission-free automotive propulsion systems using the latest lithium battery technology, congratulates GM on being the SECOND company to break the Triple Mileage Barrier. According to Ron Cerven, Chief Engineer, "It is great to see a big player like GM following in our footsteps and breaking the Triple Mileage Barrier."
EV Innovations became the first company to get over 100 MPG when on June 17th 2009, the 2010 LiV Wise achieved 211 miles, actually driven on one single charge. EVII's Director of Government Sales, Holly J. Armstrong, said that she is "certain that having a production Plug In EV that gets over 200 actual driving miles on a single charge, has to be the reason why EV Innovations is the current sole bidder on the upcoming 2010-2015 Government contracts for electric vehicles."
EVII continues to lead the industry in both technology and business modeling. In some instances, the LiV Wise is the only NHTSA compliant, highway capable sedan available for purchase or lease on Federal, State and Local levels. EVII is organizing up for maximum production, as it estimates over 10,000 LiV Wise models will be purchased or leased by the various government agencies.
MUSCLE FLEX INCORPORATED (OTC: MFLI)
"Up 11.11% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/MFLI.php
Company Profile: http://www.otcpicks.com/muscle-flex-inc.htm
Muscle Flex Inc. brings new products to market using direct response TV infomercials specializing in the health, fitness, wellness and hygiene sectors. As well, Muscle Flex Inc. develops and creates general television content for network and cable television distribution. Muscle Flex's corporate strategy is to develop new and innovative products for sale and distribution via its proprietary direct response marketing system and the creation of television media and shows for general network and cable broadcast.
MFLI News:
August 20 - Muscle Flex Inc. Prepares for The BUDDY Tablet Caddy™ September 2009 Infomercial Launch and Provides a Complete BUDDY™ Update
Muscle Flex Inc. (OTC: MFLI) announced that it is preparing for the September 2009 infomercial launch for The BUDDY Tablet Caddy and is providing a detailed update as to its release.
Muscle Flex Inc. is in the final stages of script development for The BUDDY Tablet Caddy short form infomercial (60 and 120 seconds) and anticipates the filming to occur during the first or second week of September. Preparations for the initial TV media campaign for The BUDDY are currently being formulated. The initial test of The BUDDY Tablet Caddy infomercial shall be run in a number of different markets and focus on those that are best suited from a demographic and geographic perspective. It is expected to run for 2-4 weeks and provide sales data that will allow Muscle Flex Inc. to determine what and if any adjustments are to be made.
On August 18, 2009, Muscle Flex Inc. announced that Danny Sarnoff, grandson to the legendary and "father of television" David Sarnoff, will be working with the company in directing and producing The BUDDY infomercial from script right to screen. To date, the scripting, filming and preparations for The BUDDY infomercial have been beyond expectations. Muscle Flex Inc. and Danny Sarnoff anticipate additional projects between them as The Buddy Tablet Caddy project nears completion and a successful launch is orchestrated.
Muscle Flex Inc. is anticipating strong sales numbers for The BUDDY Tablet Caddy. Muscle Flex Inc.'s initial informal research study of The BUDDY Tablet Caddy employed a series of questions designed to determine the potential response from a diverse range and random sample of consumers. The results were exceedingly positive in that the majority of people surveyed said they would purchase The BUDDY Tablet Caddy as a TV product offering. The results skewed even more favorably when the full "As Seen on TV" BUDDY Tablet Caddy offer was told to them at the conclusion of the survey resulting in excess of an 87% favorable purchase rating.
August 19 - Muscle Flex Inc. Prepares to Release Details on Two Additional 'As Seen on TV' Product Releases
Muscle Flex Inc. (OTC: MFLI) announced that it is preparing to release details on its second value priced "As Seen on TV" product. This second direct response low cost product release is scheduled to hit national TV after The BUDDY Tablet Caddy™ release in September 2009. The second "As Seen on TV" product is a "Lifestyle & Beauty" device that is to be released in late 2009. Additionally, Muscle Flex Inc. is preparing to add what it describes as a "flagship" product line. Details are being finalized on the newest Muscle Flex flagship product that Muscle Flex Inc. expects will form part of its core direct response product offerings.
"We are moving quickly to release our first three 'As Seen on TV' value products. The BUDDY Tablet Caddy is the first of these three and we are very close to releasing details on our second," commented Danny Alex, CEO of Muscle Flex Inc. "Even more exciting is the new flagship product line that Muscle Flex Inc. expects will form an integral part of its core product offerings. This product line will be delivered in a full 30 minute infomercial format and will showcase the exciting types of products Muscle Flex Inc. is bringing to market."
GREEN STAR ALTERNATIVE ENERGY INCORPORATED (OTC: GSAE)
"Up 24.00% in morning trading"
Detailed Quote: www.otcpicks.com/quotes/GSAE.php
Company Profile: http://www.otcpicks.com/Newsletter/GSAE_eProfile_091708.htm
Green Star Alternative Energy is an environmentally conscious, renewable energy producer. The Company is working to develop more than 300 MW (megawatts) of clean electricity through wind energy. The corporate revenue model is two-fold: the use of a renewable resource allows not only for the creation of environmentally friendly energy, but the granting of carbon (greenhouse gas) emission credits which may be traded and sold. Green Star is pursuing a significant opportunity to provide clean energy to the growing Republic of Serbia and neighbouring European countries. Through a joint venture with key wind farm and power trading company Notos, Green Star will become the nation's first developer of wind power. GSAE is focussed on green technology and sustainable energy programs like wind turbines, hydro electric power generation, and other renewable electricity models.
GSAE News:
August 11 - CEO of Green Star Alternative Energy Conducts Exclusive Webcast Interview with The Green Baron Report
Green Star Alternative Energy, Inc. (OTC: GSAE) ("GSAE" or the "Company") announces that its CEO Mike Andric has conducted an exclusive new audio-taped webcast interview so that GSAE shareholders and the investment community can learn more about the Company’s recent developments and growth plans. Unrestricted access to the webcast is now available on the “Webcasts” page at www.TheGreenBaron.com. This webcast is also available at www.StrictlyStocks.com, "Where Wall Street speaks to the World."
The Green Baron Report also issued a new “Stock Pick” profile dated Tuesday, August 4th, 2009 to its members and is available on their website. The report focused on how Green Star is moving forward to develop wind energy projects to the under supplied market in Serbia. The report also detailed how its Joint Venture with Notos, a private Serbian company dedicated to renewable energy, enables Green Star to establish a leadership role in the development and supply of wind power in Serbia and the Balkan Peninsula.
NAVSTAR TECHNOLOGIES INCORPORATED (OTC: NVSR)
"Up 10.61% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/NVSR.php
Company Profile: http://www.otcpicks.com/navstar-technologies/navstar-technologies.htm
NavStar is focused on the creation of GPS products and services that provide wireless tracking of vehicles, equipment, and other valuable and personal assets. The goal is to be a total solutions provider.
NVSR News:
August 20 - NavStar to Reward Loyal Shareholders
NavStar Technologies, Inc. (OTC: NVSR), a multinational firm focused on developing and commercializing asset tracking and monitoring devices for vehicles and high value cargo, announced that discussions are underway to consider a possible stock dividend to shareholders.
According to the company, this action is being taken to acknowledge the continued success in reaching distribution agreements with partners in Mexico, Ecuador, Japan, US and Korea and for the loyal support and patience of shareholders. The share price of the company has recently increased to reflect these achievements and plans are underway to issue a stock dividend to shareholders. The board of directors will provide an update to shareholders within days on the results of these discussions.
SGD HOLDINGS LIMITED (OTC: SGDH)
"Up 6.12% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/SGDH.php
Company Profile: http://www.otcpicks.com/sgd-holdings/sgd-holdings.htm
SGD Holdings, Ltd. is a holding company which owns and operates through its wholly-owned subsidiary, Ecopaper, Inc. (www.ecopaper.com). Its goal is to acquire new technologies which can positively impact the environment either through internal development or by acquisition.
SGDH News:
August 18 - SGD Holdings, Ltd. Subsidiary Ecopaper, Inc. Co-Develops Post Consumer Toilet Paper With Latin America
SGD Holdings, Ltd. (OTC: SGDH) announced that its wholly-owned subsidiary Ecopaper, Inc. has entered into an exclusive manufacturing agreement with a Latin American paper producer. Ecopaper co-developed a 100% post consumer toilet paper that has no harmful environmental effluents.
SGD Holdings, Ltd. anticipates a U.S. distribution agreement within the next 30 days.
"This is primarily a large institutional market for our eco-friendly toilet paper. We fully expect significant sales from large institutional purchasers like universities, municipalities and janitorial supply companies," stated Harry Johansing, CEO of SGD Holdings, Ltd.
ABOUT ECOPAPER, INC.
Ecopaper, Inc. is the first company in the history of the paper industry to create and market treeless paper of a superior quality. Every page of Ecopaper is smooth, acid-free, durable, chemical-free and made in Costa Rica. Ecopaper, Inc. has developed an innovative and economically feasible option for the removal of 230,000 tons of agro-industrial waste that is dumped yearly in Costa Rica alone. The company's challenge is to invent new processes and create paper from exotic tropical fibers from waste materials in new textures and tones for consumers. The results of processing these exotic tropical fibers are items that both appeal to the consumer and positively impact the environment.
MULTICELL TECHNOLOGIES INCORPORATED (OTCBB: MCET)
"Up 234.12% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/MCET.php
MultiCell Technologies, Inc., a biopharmaceutical company, develops and commercializes therapeutics based on a portfolio of patented drug development technology platforms. It involves in the research and development of degenerative neurological diseases, including multiple sclerosis (MS) and cancer. The company’s therapeutic pipeline includes MCT-125, a Phase IIb therapeutic candidate for the treatment of primary multiple sclerosis-related fatigue; MCT-175, a preclinical therapeutic candidate for the treatment of relapsing-remitting MS; MCT-465, a preclinical adjuvant therapeutic candidate for the treatment of TLR3+ cancers; and MCT-475, a preclinical therapeutic candidate for the treatment of TLR3+ breast cancer. In addition, it has patented the ‘Sybiol’ synthetic bio-liver device to produce therapeutic proteins using BioFactories technology. The company was formerly known as Exten Ventures, Inc. and changed its name to MultiCell Technologies, Inc. in April 2004. MultiCell Technologies, Inc. was founded in 1962 and is based in Woonsocket, Rhode Island.
MCET News:
August 19 - MultiCell Technologies is Granted U.S. Patent for Immortalized Human Liver Cell Lines
MultiCell Strengthens Its Liver Cancer Drug Target Identification and Cancer Stem Cell Research Program
MultiCell Technologies, Inc. (OTCBB: MCET) announced that it has been granted U.S. patent 7,566,567 by the United States of America Patent and Trademark Office covering its Fa2N-4 and Ea1C-35 immortalized human hepatocyte cell lines.
The Fa2N-4 and Ea1C-35 immortalized human hepatocyte cell lines were derived from normal human liver cells, and are nontumorigenic, stable in culture, and produce therapeutic plasma proteins in cell culture. The Fa2N-4 cell line has also been engineered to function as a proxy for normal human liver cells for use in performing drug toxicity assays. MultiCell has licensed several pharmaceutical companies rights to use the Fa2N-4 cell line for drug toxicity applications including Pfizer, Bristol-Myers Squibb, and Eisai Pharmaceuticals. MultiCell licensed Corning, Inc. to sell the Fa2N-4 cell line and media within the drug discovery and life science research markets for drug toxicity (Tox) applications as well as for drug adsorption, distribution, metabolism and excretion (ADME) studies. MultiCell retained worldwide exclusive ownership of the Fa2N-4 and Ea1C-35 cell lines for all applications other than ADME/Tox, including drug target identification and using the cell lines for the production of therapeutic plasma proteins.
MultiCell also owns exclusive worldwide rights to two issued U.S. patents (6,872,389 and 6,129,911), one U.S. patent application (U.S. 2006/0019387A1), and several corresponding issued and pending foreign patents and patent applications related to the isolation and differentiation of human liver stem cells. MultiCell previously announced it had entered into a cooperative research and development agreement with Maxim Biotech, Inc. to develop products for the study of human liver stem cells and human liver cancer.
The role of liver stem cells in the carcinogenic process has recently led to a new hypothesis that hepatocellular carcinoma in humans arises by maturation arrest of liver stem cells. "MultiCell intends to use its human liver cell and liver stem cell assets to identify therapeutic targets and new drug candidates specifically targeting the treatment of primary liver cancer and intrahepatic bile duct cancer," said Jerry Newmin, Chairman & CEO of MultiCell Technologies. "We believe our engineered human liver cell lines will play an important role as proxies for normal human liver cells in our effort to identify drug targets."
The National Cancer Institute (NCI) in 2008 stated there were approximately 21,400 new cases of hepatocellular carcinoma and intrahepatic bile duct cancer in the United States, and approximately 18,400 of those cases resulted in death. Hepatocellular carcinoma, resulting from Hepatitis B and Hepatitis C infection, is the most common cancer in some parts of the world, with more than 1 million new cases diagnosed each year. The NCI also reports that hepatocellular carcinoma is associated with cirrhosis of the liver in 50% to 80% of patients.
BEBIDA BEVERAGE COMPANY (OTC: BBDA)
"Up 42.86% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/BBDA.php
The company, formerly known as Fortis Enterprises, was founded in 2000 and is based in Casselberry, Florida. On Sept. 4, 2008, Renovo Holdings announced that the company had changed its name to Bebida Beverage Company and would be locating the base of the company's North American presence in Las Vegas, NV. Bebida Beverage Company hopes to concentrate operations on the bottled water and enhanced beverage markets of North and South America. Bebida's management will focus the company's business efforts within the United States and key target markets within Latin America.
BBDA News:
August 11 - Bebida Beverages Says CHILLAX With a KOMA UNWIND in 2009
Bebida Beverages Company (OTC: BBDA) and its Koma Unwind brand have announced final can design and flavors have been choose and a September full production is now scheduled for Koma Unwind a brand new "Chillaxation Drink Upon the purchase of Bebida Beverages.
CEO Brian Weber had made early on changes to the product portfolio and the direction of the company for the future growth, prosperity and increased shareholder value.
"We got a little ahead of ourselves when we made this change from an energy drink to a relaxation drink early on,” Weber said. “With the economy picking up, designers and flavor houses at capacity, it took a bit longer for us to get the final product where we wanted.”
“We are very happy with the final product and now taking orders from our many distributors looking to add Koma Unwind to their portfolio in the coming months,” Weber added.
Another change aside from design and flavor recently has been the down size from 20 oz bottle to a 12 oz can. “After extensive research it was really a no brainer, as most people unwinding don't care to drink so much liquid before sleep or 'Chillaxing,'” said VP Daisy Ramirez.
Bebida is also excited about continued interest in its products: Potencia Energy Drink, Potencia Blast Energy Shot, Koma Unwind & Piranha Water. The company has been in talks with several national C-Store retailers about co-branding with its NASCAR Camping World Truck Series team and driver. The opportunities for massive media exposure during the NASCAR events along with the marketing rollout make these deals unbelievably viable for retailers. Their investment in Bebida’s team is more about shelf space and purchase orders than hard cash, which during these economic recovery times is more viable.
“It's pretty simple, they purchase our products (which they do anyway) we give them national media exposure and a rallying point with our race team,” said Weber. “We are always looking for retailers that are interested in participating in these type deals.”
Potencia Energy Drink is a 3-year-old all natural fruit energy drink developed for Latino's but loved by everyone! With the initial flavor of Tamarind and the second flavor mandarin due out soon.
Bebida Beverages Co. is the maker and developer of several beverages, including Piranha Water, Guppy Water, Koma Unwind (Chillaxation Beverage) and Koma Shot.
UNIVERSAL DETECTION TECHNOLOGY (OTCBB: UNDT)
"Up 41.03% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/UNDT.php
Universal Detection Technology is a developer of monitoring technologies, including bioterrorism detection devices. The company on its own and with development partners is positioned to capitalize on opportunities related to Homeland Security. For example, the company, in cooperation with NASA, has developed a bacterial spore detector that detects certain biohazard substances. The company is also a reseller of handheld assays used for detection of five bioterrorism agents, radiation detection systems, and antimicrobial products.
UNDT News:
August 20 - Universal Detection Technology Signs Distribution Agreement With Strategic Response Initiatives
Bio-terrorism Detection Equipment Recently Certified by Department of Homeland Security Will be Available to Major Defense, Public and Private Organizations
Universal Detection Technology (OTCBB: UNDT), a developer of early-warning monitoring technologies to protect people from bioterrorism and other infectious health threats and provider of counter-terrorism consulting and training services, announced that it has signed a distribution agreement with Strategic Response Initiatives, a New York based defense firm specializing in all phases of emergency preparedness planning for a wide range of defense, public and private sector organizations.
Under the new agreement, Strategic Response Initiatives will market and distribute Universal Detection Technology's Bio-Weapons Detection Systems to a wide range of accounts, including the Department of Homeland Security, Department of Defense, New York and New Jersey state governments and various private defense contractors. SRI will also be submitting Universal Detection Technology's equipment to the Guardian Installation Protection Program and to Hazardous Incident Response Equipment.
"Our partnership with Strategic Response Initiatives proves that Universal Detection Technology is committed to bringing the latest technology in early detection bioterrorism monitoring to those government, public and private organizations at the forefront of emergency preparedness and response," said Jacques Tizabi, CEO of Universal Detection Technology. "SRI's specific expertise in weapons of mass destruction is a major component to our working relationship."
SRI's customers include Department of Homeland Security, U.S. State Department, U.S. Marine Corps Chemical Biological Incident Response Force (CBIRF) and NATO forces in Afghanistan.
Available biodetection technology to SRI customers will be Universal Detection Technology's five agent handheld biodetection kits, which recently received certification by the Department of Homeland Security.
"Strategic Response Initiative's partnership with Universal Detection Technology is bringing the latest state-of-the-art bioterrorism technology to the defense contract market," said SRI founder and CEO Robert L. Domenici, a retired U.S. Army lieutenant colonel. "This kind of technology is critical to the advancing complexities of first responders, defense and counter-terrorism."
ANIKA THERAPEUTICS INCORPORATED (NASDAQ: ANIK)
"Up 43.22% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/ANIK.php
Headquartered in Bedford, Mass., Anika Therapeutics, Inc. develops, manufactures and commercializes therapeutic products for tissue protection, healing and repair. These products are based on hyaluronic acid (HA), a naturally occurring, biocompatible polymer found throughout the body. Anika’s products include ORTHOVISC®, a treatment for osteoarthritis of the knee available internationally and marketed in the U.S. by DePuy Mitek; HYVISC®, a treatment for equine osteoarthritis marketed in the U.S. by Boehringer Ingelheim Vetmedica, Inc.; a family of aesthetic dermatology products for facial wrinkles and scar remediation marketed in the U.S. by Coapt Systems, Inc.; AMVISC®, AMVISC® Plus, STAARVISC™-II and Shellgel™ injectable viscoelastic HA products for ophthalmic surgery; INCERT®, an HA-based anti-adhesive for surgical applications; ORTHOVISC® mini a treatment for osteoarthritis targeting small joints and available in Europe; MONOVISC™ a single-injection osteoarthritis product based on Anika’s proprietary cross-linking technology and available in Europe, Turkey, and Canada; and next generation products for joint health and aesthetic dermatology based on the Company’s proprietary, chemically modified HA.
ANIK News:
August 18 - Anika Therapeutics Receives Health Canada Approval for MONOVISC
Represents the first approval in North America for its Single-Injection Osteoarthritis Treatment
Anika Therapeutics, Inc. (Nasdaq: ANIK), a leader in products for tissue protection, healing and repair based on hyaluronic acid (HA) technology, announced that it has received Health Canada approval for MONOVISC™, its single injection viscosupplement approved for the treatment of osteoarthritis of the knee. Anika expects to launch MONOVISC this month through its long-term ORTHOVISC® distribution partner in Canada, Rivex Pharma Inc., the specialty drug distribution division of Aurora, Ontario-based Helix BioPharma Corp. (TSX: HBP). MONOVISC has been broadly available in the European Union since the second quarter of 2008.
“We are very pleased to be the exclusive distributor of MONOVISC in the Canadian market and will begin aggressively marketing it immediately,” said Bill Chick, VP Product Distribution for Helix BioPharma Corp. “We believe that both patients and physicians stand to benefit from MONOVISC’s unique features: patients will welcome fewer office visits and lower treatment costs, while physicians will appreciate the simplicity of the single-injection regimen.”
“Health Canada approval marks an important next step as we continue to expand the geographic reach of our novel osteoarthritis treatment therapy and establish MONOVISC as the premier single-injection product on the market worldwide,” said Charles H. Sherwood, Ph.D., Anika’s President and Chief Executive Officer. “We are successfully moving forward on our goal of achieving FDA approval for MONOVISC in the U.S. The initial PMA modules have been submitted to the FDA and are currently under review. We expect to submit the final module containing the clinical study data prior to year-end 2009. We are confident that MONOVISC will be as well received in North America as it has been in Europe.”
The Company previously announced that it has completed the clinical segment of the U.S. pivotal trial for MONOVISC, and is now focused on completing the retreatment study for MONOVISC, which is designed to demonstrate the safety and benefit of repeat injections.
ABOUT MONOVISC™
MONOVISC™ is Anika’s next-generation HA-based therapy for treating osteoarthritis that features enhanced durability in a safe, easy-to-use, single injection regimen. MONOVISC is made from highly purified, non-animal, natural hyaluronan. Hyaluronan occurs naturally throughout the body, especially in articular cartilage, synovial fluid in joints and in the skin.
HELICOS BIOSCIENCES CORPORATION (NASDAQ: HLCS)
"Up 29.00% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/HLCS.php
Helicos BioSciences is a life science company focused on innovative genetic analysis technologies for the research, drug discovery, and diagnostic markets. Helicos' proprietary True Single Molecule Sequencing (tSMS)(TM) technology allows direct measurement of billions of strands of DNA, enabling scientists to perform experiments and ask questions never before possible. Helicos is a recipient of the $1,000 genome grant and is committed to providing scientists the tools to unlock the era of genomic medicine. The company's corporate headquarters are located at One Kendall Square, Building 700, Cambridge, MA 02139, and its telephone number is (617) 264-1800.
HLCS News:
August 20 - Ontario Institute for Cancer Research Takes Delivery of a Helicos Genetic Analysis System
Leaders in the field of cancer genomics to leverage benefits of single molecule sequencing technology
Helicos BioSciences Corporation (Nasdaq: HLCS), a life science company focused on innovative genetic analysis technologies, announced the placement of a Helicos™ Genetic Analysis System at the Ontario Institute for Cancer Research (OICR) with Drs. Tom Hudson and John McPherson.
“We are very excited to be working with such a distinguished institution on the application of our technology to the study of cancer genomics” stated Ron Lowy, Helicos Chief Executive Officer.
The Helicos Genetic Analysis System is the world’s first and only commercially available, single molecule sequencing technology, and enables scientists to conduct revolutionary studies in the fields of genome biology, cancer research, common diseases, and microbiology without DNA ligation or amplification. Genetic analysis with Helicos’s technology eliminates the biases, complexity and errors introduced by DNA amplification, requires minute amounts of starting material, and provides the most direct and accurate view of biological samples.
“The translational cancer research we are conducting at our center can benefit greatly from the advantages of single molecule sequencing” stated Tom Hudson, President and Scientific Director of the OICR. “We hope to use this technology for the unbiased and comprehensive characterization of tumor samples to ultimately lead to discoveries that have a clinical impact.”
ABOUT THE ONTARIO INSTITUTE FOR CANCER RESEARCH
The Ontario Institute for Cancer Research is a new research institute, moving Ontario to the forefront of discovery and innovation. It is dedicated to research in prevention, early detection, diagnosis and treatment of cancer. OICR is a not-for-profit corporation funded by the Government of Ontario through the Ministry of Research and Innovation.
GOLDEN DRAGON HOLDINGS INCORPORATED (OTC: GDHI)
"Up 30.00% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/GDHI.php
Golden Dragon Holdings, Inc. (GDHI) is a USA publicly traded company that owns and operates Golden Dragon Food & Beverage Import & Export Company of Hong Kong, Ltd. (GDHK) in central Hong Kong. Golden Dragon Holdings, Inc. has agreements with USA food manufacturers. GDHI acts as a buying agent for GDHK, negotiating vendor contracts and services with USA food and beverage industry partners. The company purchases goods and services directly from Golden Dragon Holdings, Inc. The Hong Kong Company plays a strategic role in the importation of products into the Chinese market by leveraging the Closer Economic Partnership Arrangement (CEPA) with China. We distribute some of the most popular USA food and beverage brand products directly into the hypermarkets, supermarkets and convenience stores in China. We are responsible for order fulfillment for our clients in China, as well as providing advertising and promotion (A&P) services for our USA food and beverage products.
GDHI News:
August 20 - Golden Dragon Holdings, Inc. Signs Distribution Agreement With Haorizi Trade Corporation
Golden Dragon Holdings, Inc. (OTC: GDHI) announces that it has signed a distribution and logistics agreement with the Haorizi Trade Corporation www.haorizi.com, a subsidiary of Good Life China. Under this agreement, GDHI will commence the sales and marketing of its products in over 500 convenience stores operated by Haorizi in Beijing.
"We are excited about the partnership with Haorizi; they have tremendous strength and experience in the food and beverage distribution and logistics industry in China. With this partnership we can focus on promoting our products and driving sales which is our true core competency," stated Mr. Frank Yglesias CEO.
ABOUT HAORIZI
Haorizi Trade Corporation (HTC) was established in 1998. Its major business is to provide IT and logistics service for short-term consuming products providers and retailers. Haorizi is one of most successful and fastest growing chain of Convenience Stores in rural areas of Hebei Province, China.
The Company has enjoyed meteoric growth rates over the last 10 years, growing from a mere 8 stores in 1999 to almost 1,600 in 2007, becoming the largest chain store network of convenience stores serving more than 2.4 million people in the rural areas of China.
The Company expects to continue rapid expansion of its retail footprint through the next several years, and plans to begin launching stores in large urban areas beginning in 2008. Current plans call for the Company to expand to 2,200 franchised stores in 2008, and reach upwards of up to 15,000 locations by the end of 2010.
Net Profit is currently projected to exceed the fiscal plan of $2.29 million USD for the 2007 fiscal year by a significant margin, and increase to over $25 million USD by 2011.
OTCPicks.com is located at 3533 Twin Lakes Drive, Prosper, TX 75078, Telephone: (972) 546-3740, Email: Publisher@OTCPicks.com.This email address is being protected from spam bots, you need Javascript enabled to view it.
DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the "SEC") or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. OTCPicks.com makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person or that an investment such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. You are receiving this email because you have registered on OTCPicks.com or one of our affiliate companies.
The information contained in our report should be viewed as commercial advertisement and is not intended to be investment advice. The report is not provided to any particular individual with a view toward their individual circumstances. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.
Our newsletter and website have been prepared for informational purposes only and are not intended to be used as a complete source of information on any particular company. An individual should never invest in the securities of any company profiled based solely on information contained in our reports. Individuals should assume that all information contained in the report about profiled companies is not trustworthy unless verified by their own independent research.
Any individual who chooses to invest in any securities should do so with caution. Investing in securities is speculative and carries a high degree of risk; you may lose some or all of the money that is invested. Always research your own investments and consult with a registered investment advisor or licensed stock broker before investing.
Information contained in our report will contain "forward looking statements" as defined under Section 27A of the Securities Act of 1933 and Section 21B of the Securities Exchange Act of 1934. Subscribers are cautioned not to place undue reliance upon these forward looking statements. These forward looking statements are subject to a number of known and unknown risks and uncertainties outside of our control that could cause actual operations or results to differ materially from those anticipated. Factors that could affect performance include, but are not limited to, those factors that are discussed in each profiled company's most recent reports or registration statements filed with the SEC. You should consider these factors in evaluating the forward looking statements included in the report and not place undue reliance upon such statements. We are committed to providing factual information on the companies that are profiled. However, we do not provide any assurance as to the accuracy or completeness of the information provided, including information regarding a profiled company's plans or ability to effect any planned or proposed actions. We have no first-hand knowledge of any profiled company's operations and therefore cannot comment on their capabilities, intent, resources, nor experience and we make no attempt to do so. Statistical information, dollar amounts, and market size data was provided by the subject company and related public information sources which we believe to be reliable but we cannot guarantee the accuracy of the information. To the fullest extent of the law, we will not be liable to any person or entity for the quality, accuracy, completeness, reliability, or timeliness of the information provided in the report, or for any direct, indirect, consequential, incidental, special or punitive damages that may arise out of the use of information we provide to any person or entity (including, but not limited to, lost profits, loss of opportunities, trading losses, and damages that may result from any inaccuracy or incompleteness of this information). We encourage you to invest carefully and read investment information available at the websites of the SEC at http://www.sec.gov and FINRA at http://www.finra.org.
Disclosure: OTCPicks.com has been compensated a total of two thousand five hundred dollars for a previous campaign and two thousand five hundred dollars by a third party (BlueWave Advisors) for a current EVII advertising and promotional campaign. OTCPicks.com has been compensated three thousand five hundred dollars from Dana Alex for MFLI advertising and promotional services. OTCPicks.com has been compensated eight thousand dollars by the company for GSAE advertising and promotional services. OTCPicks.com has recently been compensated five thousand free trading shares from Onyx Consulting for GSAE advertising and promotion. OTCPicks.com has been compensated eight thousand dollars by a third party (Mickey Reno) for NVSR advertising and promotional services. OTCPicks.com is being compensated eight thousand dollars by a third party (Stock Awareness Group) for SGDH advertising and promotional services. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. OTCPicks.com is a website partially owned by BlueWave Advisors, LLC, a financial public relations firm. BlueWave Advisors, LLC, its principal and/or its affiliates will hold positions in the company profiled and may buy or sell securities at any time without notice.
